Since its establishment in 1992 the Colorado SPORE Tissue Bank and Biomarkers Core Laboratory (TBBC) has consistently aimed to 1. provide well characterized tissues and products derived from those tissues to SPORE investigators, 2. assess status of submitted specimens by histological, immunohistochemical and fluorescence in situ hybridization, 3. link specimens to clinical data including outcomes in rigid compliance with standards for maintenance of patient confidentiality and informed consent. The development of targeted treatments has engendered an urgent need to know the status of the targeted pathway, the most striking examples of which are tyrosine kinase receptor and arachidonic acid pathways. RNA, DMA and protein biomarker status can efficiently be analyzed using core equipment and standardized methods in a single core laboratory. The Core will accordingly perform standardized molecular tests including quantitative RT-PCR and mutational analysis on extracts of tissue specimens obtained in support of individual SPORE research projects. Data from this testing is centrally tracked and distributed to SPORE clinical and basic science investigators who may then incorporate these data into hypothesis generation and testing. The expanded role of the Core in biomarker testing has prompted a name change for the core to Tissue Bank and Biomarkers Core Laboratory. The Core provides specimens and testing results for invasive tumors and is the central biorepository for unique and actively accruing early detection and chemoprevention trials for both the Colorado SPORE and the national SPORE program, collecting data and specimens from high risk patients without carcinoma at the time of enrollment. The Core is a unique source of biological materials that are used to investigate molecular changes that accompany and may predict invasive tumor. Specific services provided by the Core include consenting and enrollment of patients into tissue collection trials, preparation of kits for efficient sample collection and storage, sample procurement including but not limited to retrieval of tissue from operating and bronchoscopy suites, barcoding, accessioning and proper storage of SPORE specimens, histological sectioning and diagnosis of SPORE tissue samples, immunohistochemistry, and fluorescence in situ hybridization (FISH). In addition, specimens are prepared for RT-PCR, mutational analysis and oligonucleotide microarray studies required in the SPORE projects. Finally, specimens and data, including images (see Bronchial Map Project) are tracked through the central SPORE computer system and are available to SPORE investigators for outcome and clinicoepidemiological correlations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Oweida, Ayman; Lennon, Shelby; Calame, Dylan et al. (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6:e1356153
Blakely, Collin M; Watkins, Thomas B K; Wu, Wei et al. (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693-1704
Tan, Aik-Choon; Vyse, Simon; Huang, Paul H (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 22:72-84
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Gautschi, Oliver; Milia, Julie; Filleron, Thomas et al. (2017) Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 35:1403-1410
Li, Howard Y; McSharry, Maria; Bullock, Bonnie et al. (2017) The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res 5:767-777
McCoach, C E; Blumenthal, G M; Zhang, L et al. (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707-2714
Vaishnavi, Aria; Schubert, Laura; Rix, Uwe et al. (2017) EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77:3551-3563
Bruno, Tullia C; Ebner, Peggy J; Moore, Brandon L et al. (2017) Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res 5:898-907

Showing the most recent 10 out of 397 publications